🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Ireland / NCT07457424
Active, not recruiting Observational

Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)

NCT07457424 · tracked via the Priya Life Science Ireland tracker
Sponsor
University College Dublin
Phase
Observational
Started
2022-02-17
Last updated
2026-05-15

Condition(s) studied

Metabolic DiseaseObesity & Overweight

Investigational drug(s) / intervention(s)

semaglutide 1 mg weekly injection

semaglutide 1 mg weekly injection: Initiation of semaglutide treatment with weekly injection. The patient starts at 0.25 mg for 4 weeks and then the dose escalates at 0.5 mg. The maximum dose of 1 mg is reached at week 12. The patients decided to undergo the treatment before they were recruited in the study.

Study summary

Ingestion of food instigates the release of a battery of enteroendocrine peptide hormones that help control gut motility and digestive secretion. Peptide hormone products of the enteroendocrine L-cell and GLP-1 in particular, play multiple roles in relation to the regulation of pancreatic islet function and gastric emptying and the induction of satiety pathways in the central nervous system The mechanism of action of GLP-1 RAs on food intake reduction is mainly mediated through both peripheral and central nervous system (CNS) pathways. GLP-1 RAs directly stimulates POMC neurons and inhibits neuropeptide-Y (NPY) and Agouti-related peptide (AgRP) neurons in the arcuate nucleus resulting in a reduction in hunger and increases in fullness4.

While there were studies which indirectly measured the changes of food preference and eating behaviour in humans after using GLP-1 RAs via visual analogue scales (VAS) or Patient's Experiences Questionnaires the investigators found there is a necessity to conduct the studies to do direct measurements of the changes of food preference and eating behaviour. Direct measures of an altered food selection in humans after using GLP-1 RAs have virtually not been performed likely due to the significant methodological and conceptual challenges they pose to researchers and study design. However, direct measures represent an essential component in the attempt to understand how GLP-1 RAs alters eating and diet selection which is the main reason of conducting this study. This innovative experiment will be a critical and a novel test of the explicit experience of humans with high-sugar high-fat fluids after using GLP-1 RAs and its potential role for the understanding of possible mechanisms determining post-treatment outcome such as weight loss.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18 to 75 * Treatment Group: BMI \> 30 kg/m2 and clinically indicated for GLP-1 RA's treatment. * Controls with obesity (BMI ≥ 30 kg/m2) with no history of GLP-1 RA's treatment. * Healthy normal weight controls (BMI \< 25 kg/m2) with no history of using GLP-1 RAs * Independently mobile * Capacity to consent to participate Exclusion Criteria: * Pre-treatment factors impairing the ability to consume meal such as Significant dysphagia * Gastric outlet obstruction * Systemic or gastrointestinal condition which may affect food intake or preference * Pregnancy or lactation (At the beginning of each study visit, a urine pregnancy test will be performed for all female participants). * Active and significant psychiatric illness including substance misuse * Significant cognitive or communication issues * Medications with documented effects on food intake or food preference * History of significant food allergy and certain dietary restrictions (except for lactose intolerance)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Research Centre Dublin Dublin
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07457424 on ClinicalTrials.gov ↗ ← All trials in Ireland